Navigation Links
Perrigo Announces FDA Final Approval Of Tris Pharma's Dextromethorphan Polistirex Extended-Release Oral Suspension
Date:5/30/2012

ALLEGAN, Mich., May 30, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that the U.S. Food and Drug Administration has granted final approval to Tris Pharma for its abbreviated new drug application (ANDA) for Dextromethorphan Polistirex Extended-Release Oral Suspension, the store brand equivalent to Reckitt Benckiser's Delsym® suspension. As the exclusive marketer and distributor of this product for the store brand over-the-counter (OTC) market in the United States, Perrigo expects to begin shipping its product during its first fiscal quarter of 2013.

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO)

Litigation between Tris and Reckitt Benckiser is ongoing in the United States District Court for the District of New Jersey, where the court has previously granted summary judgment of non-infringement of the asserted patent claims. As the Tris ANDA was the first one submitted with a paragraph IV certification, marketing of the product is entitled to 180 days of generic exclusivity.

Delsym® is indicated for the treatment of cough due to minor throat and bronchial irritation. Perrigo estimates the past 52-weeks sales for the brand were approximately $110 million.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This approval further highlights our ability to bring new products to our consumers and reinforces our continued focus of making quality healthcare more affordable. We are pleased to add this important new product to our retail and wholesale customers' store brand product portfolios when we begin shipments to them for the upcoming cough/cold/flu season."

Tris Pharma is a technology driven specialty pharmaceutical company which pioneered sustained release in liquid and other unique dosage forms such as chewable/ODT and film strip.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream
2. Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules
3. Perrigo Company to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference
4. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
5. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
6. Perrigo Company to Present at the RBC Capital Markets Healthcare Conference
7. Perrigo Announces the Launch of Loratadine-D 12 Store Brand Labels -- the First Store Brand Launch That Compares to Claritin-D® 12
8. Perrigo Company to Present at the Leerink Swann 2012 Global Healthcare Conference
9. Perrigo Company Announces Quarterly Dividend
10. Perrigo Confirms Filing for Generic Version of Astepro® Nasal Spray and Announcement of Patent Infringement Lawsuit by Meda Pharmaceuticals
11. Perrigo Wins Summary Judgment in Generic Mucinex® Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... PUNE, India , May 3, 2016 /PRNewswire/ ... Market 2016 Research Report provides a basic overview ... manufacturing technology, post which the surgical mesh report ... the market. Complete report on Surgical ... company profiles and 98 tables and figures is ...
(Date:5/2/2016)... NEW YORK , May 2, 2016 Leading Economies ... Growth Ethiopia 10.2 Côte d,Ivoire 8.6 Uzbekistan 8 Ireland 7.8 India 7.3, ... TechSci Research, BRICS nations , which comprises of Brazil ... China and South Africa , registered the fastest ... economic slowdown in China , recession in Brazil ...
(Date:5/2/2016)... N.J. , May 2, 2016  Celsion ... development company, today announced data from the first ... escalating clinical trial (the OVATION Study) combining GEN-1, ... care for the treatment of newly-diagnosed patients with ... followed by interval debulking surgery.  In the first ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... ... Fertility Centers of New England announced today the opening of their newest ... convenient access to care for patients seeking fertility treatment in Maine. “We are delighted ... in Portland,” said Fertility Centers of New England President and CEO, Joseph A. Hill, ...
(Date:5/3/2016)... ... May 04, 2016 , ... Safety Week is an annual ... the Construction Industry Safety Initiative (CISI) and the Incident and Injury-Free (IIF) CEO ... in the industry to be leaders in safety. Statistics show that each year, ...
(Date:5/3/2016)... ... 03, 2016 , ... According to an article ... related to medical care in the hospital setting, which include excessive wait times ... staff. Commenting on this article, the founder of House Call Doctor Los Angeles, ...
(Date:5/3/2016)... ... May 03, 2016 , ... Healing Cancer in This Century ... families move toward recovery and is offered by creator and visionary Carlos Caridad. ... Talk Radio show considering medical and healing modalities of the fields of Integrative, ...
(Date:5/3/2016)... ... , ... With the opioid epidemic now at the forefront, attention has shifted ... Alcohol and its misuse causes long-term consequences for all aspects of society, from the ... 65 years and older. In addition, there is the long term affects of ...
Breaking Medicine News(10 mins):